CN101991549A - Antipyretic, analgesic and anti-inflammatory medicinal composition - Google Patents
Antipyretic, analgesic and anti-inflammatory medicinal composition Download PDFInfo
- Publication number
- CN101991549A CN101991549A CN2010105260488A CN201010526048A CN101991549A CN 101991549 A CN101991549 A CN 101991549A CN 2010105260488 A CN2010105260488 A CN 2010105260488A CN 201010526048 A CN201010526048 A CN 201010526048A CN 101991549 A CN101991549 A CN 101991549A
- Authority
- CN
- China
- Prior art keywords
- ibuprofen
- arginine
- injection
- minutes
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an antipyretic, analgesic and anti-inflammatory medicinal composition injection, wherein a molar ratio of arginine to ibuprofen is 1.01:1-1.5:1, and in particular provides a method for preparing the composition injection. The injection contains an injection subjected to high temperature sterilization and a freeze-dried powder injection subjected to low temperature freeze drying. The composition is simple in preparation and easy to control and can greatly improve the stability of composition aqueous solution, improve the bioavailability of the medicament, reduce the response time of the medicament and gain more valuable time for the treatment of patients.
Description
Technical field
The invention belongs to technical field of medicine, relate to NSAID (non-steroidal anti-inflammatory drug) ibuprofen and amino acid whose combination, the invention of this pharmaceutical composition, the autonomous innovation that indicates the ibuprofen intravenous injection has obtained important breakthrough, the present invention is applied to generate heat, pain and inflammation patient's treatment, will play great clinical value.
Background technology
Ibuprofen
Chemical name: (±)-2-(p-isobutyl phenenyl) propanoic acid
Chemical structural formula:
Molecular formula: C
13H
18O
2
Molecular weight: 206.28
Ibuprofen (Ibuprofen) has another name called the isobutylbenzene propanol, is the nonsteroidal antiinflammatory and analgesic medicine.Ibuprofen has antiinflammatory, analgesia and refrigeration function, in many tests of adopting conventional animal to implement, ibuprofen act as 16～32 times of aspirin.Ibuprofen 300mg topical can alleviate the erythema that the application of thurfyl nicotinate Emulsion causes, and effect and aspirin and ibufenac are similar in this respect.The analgesia of ibuprofen is periphery type rather than central type.This chemical compound does not have the characteristic of glucocorticoid or adrenocortical hormone stimulation.Two kinds of ibuprofen main metabolites of people do not have antiinflammatory and analgesic activities, show that ibuprofen itself is exactly an active pharmacological preparation.Its antiinflammatory, analgesia, refrigeration function are respond well, and untoward reaction is less.Ibuprofen is widely used in the world at present, becomes one of global best-selling over-the-counter drug and aspirin, acetaminophen and is listed as antipyretic analgesic three big pillar products together.Outside a good appetite suddenly appearing in a serious disease state pharmacopeia was recorded, it was also by multinational pharmacopeia such as income American and Britain, days.Ibuprofen goes on the market in Britain early than nineteen sixty-eight, and the manufacturer is a Britain The Boots Co. PLC, and commodity are called Brufen.Because it has rheumatism and analgesic analgesic curative effect concurrently, toxicity is low, uses aspects such as causing death all to be better than aspirin and acetaminophen in curative effect and overdose, thereby its market enlarges rapidly, and the record of 60,000,000 dollars of sales volumes was just created in U.S.'s listing in 1 year.Market keeps the situation of strong growth always afterwards, and to early 1980s, world's sales volume is above 300,000,000 dollars.In the later stage eighties 20th century, because the good curative effect of ibuprofen and have less untoward reaction, the U.S., Britain ratify to transfer it to nonprescription drugs by prescription drugs in succession.Subsequently, a lot of countries in the world all transfer it to nonprescription drugs, make that the market sales revenue of ibuprofen is further increased.To early 1990s, the sales volume of world market Motrin has broken through 1,000,000,000 dollars of high pointes, is to break through 1,000,000,000 dollars antipyretic analgesic the earliest.In the OTC of US and European antipyretic analgesic market, ibuprofen and acetaminophen, aspirin are three kinds of medicines of sales volume maximum, account for more than 90% of the market sales revenue at present, and wherein ibuprofen accounts for about 25%.
Ibuprofen has its oneself characteristic in clinical practice: be all antipyretic safely and effectively, when body temperature was higher than 39.2 ℃, ibuprofen was than more effective with the acetaminophen of dosage; And the longer antipyretic effect of fever time similar to aspirin but the effect than more lasting; Its analgesic activity is 16-32 a times of aspirin; Lighter to the gastrointestinal side effect, easily tolerance is that gastrointestinal irritation is minimum in this type of medicine; Its untoward reaction is lacked than aspirin and light.But its antiinflammatory action a little less than.Ibuprofen has 13 kinds of dosage forms to be put into China's OTC (over-the-counter) catalogue at present, is one of maximum OTC antipyretic analgesic of preparation variety.In national basic medical insurance medicine catalogue, ibuprofen is one of three Class A products of nonsteroidal anti-inflammatory analgetic, and two is aspirin and somedon in addition.
Though ibuprofen is having many advantages aspect analgesic, pain and the antiinflammatory, but ibuprofen is separated than indissoluble simultaneously, therefore just cause the ibuprofen solution dosage to be difficult to exploitation, be used for antipyretic-antalgic and the antiinflammatory aspect is safe and addiction is little injection simultaneously on the market seldom.The also strong this point that proved of the market situation of global nonsteroidal anti-inflammatory analgetic injection.The American market of ibuprofen injection is captured by Kanboland Medical Products Inc. at present.Nowadays, through us experimental work person's long-term exploration and practice, invented a kind of ibuprofen and arginine composition injection with independent intellectual property right.
We have carried out pharmacology test in addition: get 8 of rabbit, be divided into two groups at random, be respectively ibuprofen injection 0.06,0.18g/kg dosage group, and 4 every group, male and female half and half.Adopt consubstantiality left and right sides self matching type, rabbit left side auricular vein gives ibuprofen injection, and rabbit auris dextra edge vein gives 0.9% sodium chloride injection and organizes in contrast, is 0.9ml/kg, successive administration 7 days.Animal and injection site carried out perusal in 48,72,96 hours before administration every day and after the last administration, observe erythema, edema, congested degree and scope.Observation period finishes male and female and respectively gets the left and right sides ear of 1 rabbit, gets 3 sections blood vessels continuously together with surrounding tissue with auricular vein injection point centripetal direction, is followed successively by three sections of upper, middle and lower, every section 1cm, use 10% formaldehyde fixed, make tissue slice, examine under a microscope and have or not pathological change according to conventional method.Take the pathology photo, and, carry out safety evaluatio by following standard according to the result of perusal and histopathologic examination; The animal that stays continues to observe 14 days the same histopathologic examinations that carry out again.
The blood vessel irritation standards of grading: 1. blood vessel changes: the complete note of blood vessel endothelium and blood vessel wall 0 minute, endothelial injury note 1 minute is arranged, and thromboembolism note 2 minutes are arranged, angiorrhexis note 3 minutes.2. the blood vessel surrounding tissue changes: surrounding tissue is normally remembered 0 fen, edema note 1 minute, and hemorrhage note 2 minutes has inflammatory cell infiltration note 3 minutes.
Blood vessel irritation safety criterion: every group of every observation index score of rabbit added up, calculate and respectively organize the average value.Average mark＜0.5 is divided into nonirritant, and＜2.5 are divided into slight zest, and＜4.5 are divided into the moderate zest, and＞4.5 are divided into the severe zest.
Statistical method: ibuprofen injection administration group and the every observation index score of matched group rabbit are added up, calculate and respectively organize the average value, the promoting the circulation of blood pipe zest of going forward side by side safety is judged.
The result: ibuprofen injection group and matched group auricular vein successive administration 7 times, blood vessel and the perusal of blood vessel surrounding tissue have no significant change.Histopathologic examination, ibuprofen injection 0.06g/kg matched group 1 routine epimere, stage casing blood vessel surrounding tissue mild inflammation, the slight cell infiltration of ibuprofen injection 0.18g/kg matched group 1 routine stage casing blood vessel surrounding tissue; Ibuprofen injection 0.06g/kg dosage group 1 routine epimere, the slight cell infiltration of hypomere blood vessel surrounding tissue; Slight cell infiltration around ibuprofen injection 0.18g/kg dosage group 1 routine epimere, the stage casing blood vessel.Ibuprofen injection 0.06g/kg, the 0.18g/kg dosage group and the matched group rabbit ear are all with light inflammation, and safety evaluation is for there being slight zest.And administration group and matched group are not relatively seen notable difference, are thought of as the continuous several times injection, and diseased region is near the injection pin hole, should be due to the repeatedly stimulation of injection needle, but not due to the medicine factor.Animal blood vessels that stays and the perusal of blood vessel surrounding tissue are all no abnormal, and histopathologic examination does not have significant change yet.
By above experiment as can be known, when the mol ratio of arginine and ibuprofen was 1.01: 1～1.5: 1, the toleration of this product was better, and drug safety is reliable, along with the carrying out of follow-on test, and the safety and the effectiveness of evaluation this product that we will science.
Summary of the invention
The injection of a kind of ibuprofen and arginine composition has been invented out by our company, wherein the mol ratio of arginine and ibuprofen is 1.01: 1～1.5: 1, when finding that mol ratio when arginine and ibuprofen was greater than 1.01: 1, the stability of this product has obviously improved, relevant parameters such as character and particulate matter, related substance all do not have significant change in accelerated test and long term test, do not find the crystallize phenomenon, this product is very stable.The clinical trial of this injection proves that it has significantly accelerated the onset time of medicine, has all brought into play better effect at analgesic, ease pain, believes that this invention brings glad tidings for our pain, heating and inflammation patient.
The present invention adds ibuprofen in 50 ℃～90 ℃ waters for injection in the process of ibuprofen injection preparation, adds hydrotropy with arginine as cosolvent, makes injection through high temperature sterilize or lyophilization.Wherein the mol ratio of arginine and ibuprofen is 1.01: 1～1.5: 1.
Detailed Description Of The Invention
The present invention one: ibuprofen adds 50 ℃～90 ℃ waters for injection, after adding arginine gradually, transfer pH to 7.5-8.5, when arginine and ibuprofen mole were 1.01: 1～1.5: 1, stirring can be dissolved ibuprofen fully, become colourless clear liquid with solution after 0.05%～0.2% activated carbon adsorption, with the filtering with microporous membrane of 0.22 μ m, embedding, the inspection of semifinished product, behind high temperature sterilize, can be made into the injection of 400mg/4ml and 800mg/8ml.
The present invention two: ibuprofen adds 50 ℃～90 ℃ waters for injection, after adding arginine gradually, transfer pH to 7.5-8.5, when arginine and ibuprofen mole during greater than 1.01: 1～1.5: 1, stirring can be dissolved ibuprofen fully, becomes colourless clear liquid with solution after 0.05%～0.2% activated carbon adsorption, with the filtering with microporous membrane of 0.22 μ m, embedding, can be made into the injection that 400mg/ props up and 800mg/ props up after rolling aluminium lid at lyophilization, tamponade.
The mol ratio of compositions arginine and ibuprofen is succeeding in developing of 1.01: 1～1.5: 1 injections, has following important meaning:
1. the common both at home and abroad arginine and the compositions mol ratio of ibuprofen are 0.01: 1～0.99: 1, the arginine of our development and the compositions mol ratio of ibuprofen are 1.01: 1～1.5: 1, make the water solublity of this product better, the stability of medicine is also better, no crystallize phenomenon.
2. brufen composition injection three batch samples are all very stable in every index of 15 minutes of 121 ℃ of sterilizations, and pH value meets the medication demand fully between 7.5～8.5.
3. brufen composition injection three batch samples are very stable at-45 ℃ of cryodesiccated injections, and redissolve the back pH value between 7.5～8.5, and clarity and particulate matter are up to specification, meet the medication demand fully.
4. the mol ratio of arginine and ibuprofen is 1.01: 1～1.5: 1 a brufen composition injection, proves that through pharmacological experiment this product hemolytic and anaphylaxis all meet pharmacological regulation, and this product is safe and reliable.
5. the mol ratio of arginine and ibuprofen is 1.01: 1～1.5: 1 a brufen composition injection, has had autonomous intellectual property, can open up external medical market.
The specific embodiment
Example 1:
Ibuprofen 4.0kg adds 80 ℃ of waters for injection, add arginine 3.5kg gradually after, transfer pH to 7.0～8.5.Add the medicinal charcoal of amount of liquid medicine 0.1% (g/ml), stirred 20 minutes, coarse filtration is taken off charcoal.Add the injection water to 4000ml.Solution is extremely clear and bright through the filter of 0.22 μ m microporous filter membrane.The inspection of semifinished product, every of qualified back come embedding by 4ml.Sterilized 15 minutes for 121 ℃.Automatically leak detection, lamp inspection, full inspection.
Example 2:
Ibuprofen 4.0kg adds 80 ℃ of waters for injection, add arginine 3.8kg gradually after, transfer pH to 7.0～8.5.Add the medicinal charcoal of amount of liquid medicine 0.1% (g/ml), stirred 20 minutes, coarse filtration is taken off charcoal.Add the injection water to 4000ml.Solution is extremely clear and bright through the filter of 0.22 μ m microporous filter membrane.The inspection of semifinished product, every of qualified back come embedding by 4ml.Sterilized 15 minutes for 121 ℃.Automatically leak detection, lamp inspection, full inspection.
Example 3:
Ibuprofen 4.0kg adds 80 ℃ of waters for injection, add arginine 4.0kg gradually after, transfer pH to 8.0～9.0.Add the medicinal charcoal of amount of liquid medicine 0.1% (g/ml), stirred 20 minutes, coarse filtration is taken off charcoal.Add the injection water to 4000ml.Solution is extremely clear and bright through the filter of 0.22 μ m microporous filter membrane.The inspection of semifinished product, every of qualified back come embedding by 4ml.Sterilized 15 minutes for 121 ℃.Automatically leak detection, lamp inspection, full inspection.
Example 4:
Ibuprofen 4.0kg adds 80 ℃ of waters for injection, add arginine 3.5kg gradually after, transfer pH to 7.0～8.5.Add the medicinal charcoal of amount of liquid medicine 0.1% (g/ml), stirred 20 minutes, coarse filtration is taken off charcoal.Add the injection water to 4000ml.Solution is extremely clear and bright through the filter of 0.22 μ m microporous filter membrane.The inspection of semifinished product, every of qualified back come embedding by 4ml.The ibuprofen medicinal liquid that branch is installed is put in the freeze drying box, and pre-freeze is incubated evacuation subliming by heating after 2 hours to-45 ℃.Make temperature rise to-20 ℃ with 120 minutes, be incubated 300 minutes; Made temperature rise to-10 ℃ with 240 minutes; Be incubated 360 minutes; Make temperature rise to 10 ℃ with 240 minutes, be incubated 240 minutes; Make temperature rise to 45 ℃ with 180 minutes, be incubated 480 minutes; Insulation finishes, products temperature when temperature being set reaching unanimity, through measuring pressure rise qualified after, lyophilizing finishes.Lid is rolled in tamponade, visual inspection, check.
Example 5:
Ibuprofen 4.0kg adds 80 ℃ of waters for injection, add arginine 3.8kg gradually after, transfer pH to 7.0～8.5.Add the medicinal charcoal of amount of liquid medicine 0.1% (g/ml), stirred 20 minutes, coarse filtration is taken off charcoal.Add the injection water to 4000ml.Solution is extremely clear and bright through the filter of 0.22 μ m microporous filter membrane.The inspection of semifinished product, every of qualified back come embedding by 4ml.The ibuprofen medicinal liquid that branch is installed is put in the freeze drying box, and pre-freeze is incubated evacuation subliming by heating after 2 hours to-45 ℃.Make temperature rise to-20 ℃ with 120 minutes, be incubated 300 minutes; Made temperature rise to-10 ℃ with 240 minutes; Be incubated 360 minutes; Make temperature rise to 10 ℃ with 240 minutes, be incubated 240 minutes; Make temperature rise to 45 ℃ with 180 minutes, be incubated 480 minutes; Insulation finishes, products temperature when temperature being set reaching unanimity, through measuring pressure rise qualified after, lyophilizing finishes.Lid is rolled in tamponade, visual inspection, check.
Example 6:
Ibuprofen 4.0kg adds 80 ℃ of waters for injection, add arginine 4.0kg gradually after, transfer pH to 8.0～9.0.Add the medicinal charcoal of amount of liquid medicine 0.1% (g/ml), stirred 20 minutes, coarse filtration is taken off charcoal.Add the injection water to 4000ml.Solution is extremely clear and bright through the filter of 0.22 μ m microporous filter membrane.The inspection of semifinished product, every of qualified back come embedding by 4ml.The ibuprofen medicinal liquid that branch is installed is put in the freeze drying box, and pre-freeze is incubated evacuation subliming by heating after 2 hours to-45 ℃.Make temperature rise to-20 ℃ with 120 minutes, be incubated 300 minutes; Made temperature rise to-10 ℃ with 240 minutes; Be incubated 360 minutes; Make temperature rise to 10 ℃ with 240 minutes, be incubated 240 minutes; Make temperature rise to 45 ℃ with 180 minutes, be incubated 480 minutes; Insulation finishes, products temperature when temperature being set reaching unanimity, through measuring pressure rise qualified after, lyophilizing finishes.Lid is rolled in tamponade, visual inspection, check.
Claims (10)
1. drug combination injection that contains arginine and ibuprofen, the mol ratio that it is characterized by arginine and ibuprofen is 1.01: 1～1.5: 1.
2. be (RS)-ibuprofen, (S)-ibuprofen according to the ibuprofen in the claim 1.
3. be L-arginine, D-arginine according to the arginine in the claim 1.
4. it is 1.05: 1～1.3: 1 according to arginine in the claim 1 and ibuprofen mol ratio.
5. handle for adding 0.05%～0.2% activated carbon adsorption, 0.22 μ m filtering with microporous membrane according to this injection in the claim 1, after 121 ℃ of high temperature sterilizes or-45 ℃ of cryodesiccated freezing-dried powder injections.
6. the preparation method of analgesic a, analgesia, antiphlogistic drug combination injection, it is characterized in that earlier ibuprofen being added water for injection, and then add arginine gradually and make its dissolving make aqueous solution, through aseptic process, make injection, wherein the mol ratio of arginine and ibuprofen is 1.01～1.5: 1.
7. be (RS)-ibuprofen, (S)-ibuprofen according to the ibuprofen in the claim 6.
8. be L-arginine, D-arginine according to the arginine in the claim 6.
9. it is 1.05: 1～1.3: 1 according to arginine in the claim 6 and ibuprofen mol ratio.
10. be to add 0.05%～0.2% activated carbon adsorption, the processing of 0.22 μ m filtering with microporous membrane according to aseptic process in the claim 6, after 121 ℃ of degree high temperature sterilizes or-45 ℃ of lyophilizations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105260488A CN101991549A (en) | 2010-10-26 | 2010-10-26 | Antipyretic, analgesic and anti-inflammatory medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105260488A CN101991549A (en) | 2010-10-26 | 2010-10-26 | Antipyretic, analgesic and anti-inflammatory medicinal composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101991549A true CN101991549A (en) | 2011-03-30 |
Family
ID=43782631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105260488A Pending CN101991549A (en) | 2010-10-26 | 2010-10-26 | Antipyretic, analgesic and anti-inflammatory medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101991549A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488662A (en) * | 2011-12-16 | 2012-06-13 | 哈药集团中药二厂 | Preparation methods of ibuprofen arginine powder injection for injection |
| CN102860983A (en) * | 2011-07-08 | 2013-01-09 | 广州威尔曼新药研发有限公司 | Novel pharmaceutical composition of 2-(4- isobutylphenyl) propionic acid |
| CN103479605A (en) * | 2012-06-13 | 2014-01-01 | 四川科伦药物研究有限公司 | Dilutable ibuprofen pharmaceutical composition and preparation method thereof |
| CN104622816A (en) * | 2015-01-04 | 2015-05-20 | 济南东方开元医药新技术有限公司 | Ibuprofenlyophilized powder composition and preparation method |
| CN104666287A (en) * | 2011-07-08 | 2015-06-03 | 广州威尔曼新药研发有限公司 | Novel pharmaceutical composition of 2-(4-isobutyl phenyl) propionic acid |
-
2010
- 2010-10-26 CN CN2010105260488A patent/CN101991549A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102860983A (en) * | 2011-07-08 | 2013-01-09 | 广州威尔曼新药研发有限公司 | Novel pharmaceutical composition of 2-(4- isobutylphenyl) propionic acid |
| CN104666287A (en) * | 2011-07-08 | 2015-06-03 | 广州威尔曼新药研发有限公司 | Novel pharmaceutical composition of 2-(4-isobutyl phenyl) propionic acid |
| CN104666287B (en) * | 2011-07-08 | 2020-06-16 | 广州威尔曼新药研发有限公司 | Pharmaceutical composition of 2- (4-isobutylphenyl) propionic acid |
| CN102488662A (en) * | 2011-12-16 | 2012-06-13 | 哈药集团中药二厂 | Preparation methods of ibuprofen arginine powder injection for injection |
| CN103479605A (en) * | 2012-06-13 | 2014-01-01 | 四川科伦药物研究有限公司 | Dilutable ibuprofen pharmaceutical composition and preparation method thereof |
| CN103479605B (en) * | 2012-06-13 | 2016-01-27 | 四川科伦药物研究有限公司 | A kind of dilutable ibuprofen medicinal composition and preparation method thereof |
| CN104622816A (en) * | 2015-01-04 | 2015-05-20 | 济南东方开元医药新技术有限公司 | Ibuprofenlyophilized powder composition and preparation method |
| CN104622816B (en) * | 2015-01-04 | 2017-05-10 | 济南东方开元医药新技术有限公司 | Ibuprofenlyophilized powder composition and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023158064A (en) | Crude drug-containing pharmaceutical composition | |
| Álvarez et al. | Sketching neoteric solvents for boosting drugs bioavailability | |
| JP2021080279A (en) | Pharmaceutical composition comprising chili pepper | |
| CN101991549A (en) | Antipyretic, analgesic and anti-inflammatory medicinal composition | |
| CN103193772A (en) | Preparation method and application of substituted aryl propionic berberine ion-pair compound | |
| CN102085179B (en) | Ibuprofen injection and preparation method thereof | |
| CN102160852A (en) | Ibuprofen injection and preparation method thereof | |
| CN103622907B (en) | A kind of brufen fat emulsion injection and preparation method thereof | |
| CN106031710B (en) | The injection and preparation method thereof that a kind of fumaric acid fluorine pula is praised | |
| WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
| CN102836145B (en) | Applications of pterostilbene in preparation of medicines for preventing and treating chronic glomerular disease | |
| CN103301101B (en) | The new pharmaceutical composition of 2-(the fluoro-4-xenyl of 2-)-propanoic acid | |
| CN104418818B (en) | Parecoxib sodium anhydrous compound | |
| TWI472519B (en) | N-butylidenephthalide-containing pharmaceutical composition for treating liver injury and improving liver function | |
| CN102335114B (en) | Stable ibuprofen arginine injection and preparation method thereof | |
| CN102266285A (en) | Low excitant ibuprofen injection | |
| CN102908352A (en) | Application of terazosin or its salt in preparing drug for treating septicemia/stroke | |
| CN101569604A (en) | Dexibuprofen amino acid salt injection and preparation method thereof | |
| CN101313914B (en) | Uses and preparations of common camptotheca fruit glycosides of common camptotheca fruit extract | |
| WO1999016432A1 (en) | A drug for treating diabetic nephrosis | |
| CN103191050B (en) | A kind of zanamivir injection and preparation method thereof | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| CN113368251A (en) | Combined solvent and preparation method and application thereof | |
| CN103893767A (en) | Ibuprofen medicine composition with stable quality | |
| CN103720647A (en) | Dexibuprofen injection composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| DD01 | Delivery of document by public notice |
Addressee: Wuhan Langji Technology Development Co., Ltd. Document name: Notification of before Expiration of Request of Examination as to Substance |
|
| DD01 | Delivery of document by public notice |
Addressee: Liu Shirong Document name: Notification that Application Deemed to be Withdrawn |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110330 |